Accord Sees Benefits From Unique Portfolio

EMENA Chief Paul Tredwell Talks About How The Firm Views Its Broad Offering

With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.

Portfolio button computer keyboard
Accord EMENA head Paul Tredwell discusses the firm’s portfolio • Source: Shutterstock

Accord Healthcare believes it holds a unique position in the market thanks to a broad product portfolio that includes generics, biosimilars, hybrid medicines and specialty products, as well as complementary offerings such as digital apps for patients and pharmacists, the company’s executive vice-president for the Europe, Middle East and North Africa region, Paul Tredwell has told Generics Bulletin in an exclusive interview.

Having previously set out his strategic approach to Accord’s overall business in the year since taking over the position (see...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business